BioAge Labs (BIOA) risk factors
Item 1A of every BioAge Labs, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks78 new63 dropped
BioAge Labs focuses on developing its lead NLRP3 inhibitor BGE-102 for cardiometabolic and ophthalmic diseases. The company relies heavily on external third-party contractors and collaborators like Novartis. Significant ongoing capital needs and research and development expenses dominate the company's risk profile.
Filed Mar 24, 2026 - FY2024 10-K risk factors63 risks
BioAge Labs relies heavily on the success of its lead metabolic and obesity drug candidate, BGE-102. The company faces high clinical trial risks and intense competition in the obesity therapeutics space. Operations depend entirely on third-party manufacturers, patent protection, and ongoing capital raises to fund unprofitability.
Filed Mar 20, 2025